The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2018 | Lung cancer immunotherapy response testing: PDL-1, TMB or an alternative?
At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, gave a very interesting talk on predictive response assays for lung cancer immunotherapy. Speaking from the meeting, Prof. Hirsch highlights the take-home points of his talk, raising thought-provoking questions for further consideration. These questions include: Are all mutations immunogenically equal? Should we combine PDL-1 and TMB assays? Should alternative markers, such as CTLA4 mRNA, be used? What other aspects of immune escape need to be considered?
